tradingkey.logo
tradingkey.logo

Roche Spokesperson Says Decided To Stop Clinical Development Of Emugrobart For Spinal Muscular Atrophy & Facioscapulohumeral Muscular Dystrophy

ReutersMar 20, 2026 4:08 PM

- Roche Holding AG ROPC.S:

  • ROCHE SPOKESPERSON: DECIDED TO STOP CLINICAL DEVELOPMENT OF EMUGROBART FOR BOTH SPINAL MUSCULAR ATROPHY & FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY

  • ROCHE SPOKESPERSON: PHASE II DEVELOPMENT OF EMUGROBART IN OBESITY CONTINUES AS PLANNED

Source text: [ID:]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI